Minnesota’s new opioid law assesses a fee on drug manufacturers to pay for prevention and treatment programs — but backers are looking for additional sources of revenue.   Democratic Representative Liz Olson from Duluth:

“One of the things we did not capture in the funding mechanism of this was the opioid distributors, which play a big part in this as well and are something that we left on the table in the compromise, and I think there’s a set of folks that are very interested in going back and approaching that again next session.”

The next regular session of the legislature begins mid-February 2020.